Hinge Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Hinge Health, Inc. on May 23, 2025. The filing documents the closing of the Company's initial public offering (IPO) and the concurrent amendment and restatement of its Certificate of Incorporation and Bylaws.
Key Financial Metrics and Transaction Details
- Offering Size: 15,715,900 shares of Class A Common Stock sold in total.
- Offering Composition: 8,522,528 shares sold by the Company and 7,193,372 shares sold by selling stockholders.
- Offering Price: $32.00 per share.
- Over-Allotment: The underwriters exercised their option in full to purchase an additional 2,049,900 shares from selling stockholders.
- Gross Proceeds to Company: $272,720,896 (before deducting underwriting discounts, commissions, and estimated offering expenses).
- Proceeds to Selling Stockholders: The Company received no proceeds from the shares sold by selling stockholders.
Material Changes
The primary material change is the Company's transition to a publicly traded entity on The New York Stock Exchange under the symbol "HNGE." Additionally, the Company's governing documents (Certificate of Incorporation and Bylaws) were amended and restated effective immediately prior to the closing of the IPO.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation of the Prospectus by reference. The filing notes that the description of the Certificate of Incorporation and Bylaws is qualified in its entirety by reference to the Prospectus and the exhibits filed herewith.
Investor Verification Checklist
- Verify the net proceeds to the Company after deducting underwriting discounts and offering expenses, as only gross proceeds are listed in this summary.
- Review the "Description of Capital Stock" section in the final Prospectus (dated May 21, 2025) for details on the amended Certificate of Incorporation and Bylaws.
- Confirm the lock-up period and any restrictions on the shares sold by selling stockholders.
- Examine the full list of selling stockholders to understand the dilution impact and insider participation.